Geoffrey R. Oxnard, MD | Authors


Acquired Resistance to Osimertinib in T790M-Positive NSCLC

April 21, 2017

Geoffrey R. Oxnard, MD, discusses a study that found overgrowth of competing resistance mechanisms, such as an acquired KRAS mutation, underlies a poor prognosis subtype of acquire resistance to osimertinib in T-790M-positive non-small cell lung cancer.

Dr. Geoffrey R. Oxnard Treating EGFR-Inhibitor Resistant Patients With Lung Cancer

January 18, 2016

Geoffrey R. Oxnard, MD, discusses resistance to EGFR inhibitors in patients with lung cancer. Oxnard says resistance to treatment in lung cancer is complex, in that it can change from day to day. He cites one example as patients possibly being resistant to T790M targeted treatments to possibly a MET-related resistance.

Dr. Geoffrey R. Oxnard on When to Change EGFR TKIs

November 14, 2015

Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, talks about the treatment options for patients with lung cancer who have become resistant to their first-line treatments.